PD-1 PD-1 ligand interaction contributes to immunosuppressive microenvironment of Hodgkin lymphoma

Blood

Volumn 111, Issue 6, 2008, Pages 3220-3224

  Yamamoto, Ryo ^a   Nishikori, Momoko ^a,e   Kitawaki, Toshio ^a   Sakai, Tomomi ^a   Hishizawa, Masakatsu ^a   Tashima, Masaharu ^a   Kondo, Tadakazu ^a   Ohmori, Katsuyuki ^b   Kurata, Masayuki ^c   Hayashi, Takamasa ^d   Uchiyama, Takashi ^a  

^a KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b KYOTO UNIVERSITY HOSPITAL   (Japan)

^c KOBE CITY MEDICAL CENTER GENERAL HOSPITAL   (Japan)

^d TENRI HOSPITAL   (Japan)

^e 54 Shogoin Kawaharacho ^*  (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CD28 ANTIGEN; GAMMA INTERFERON; PROGRAMMED DEATH 1 LIGAND; UNCLASSIFIED DRUG; APOPTOSIS REGULATORY PROTEIN; CD274 PROTEIN, HUMAN; LEUKOCYTE ANTIGEN; PDCD1 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CELLULAR IMMUNITY; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; HODGKIN DISEASE; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; MALE; PRIORITY JOURNAL; T LYMPHOCYTE; ADOLESCENT; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; METABOLISM; MIDDLE AGED; PROTEIN BINDING; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD; APOPTOSIS REGULATORY PROTEINS; CELL LINE, TUMOR; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HODGKIN DISEASE; HUMANS; MALE; MIDDLE AGED; PROTEIN BINDING; SIGNAL TRANSDUCTION;

EID: 42449147063     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2007-05-085159     Document Type: Article

References (25)

1. Chen L. Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity. Nat Rev Immunol. 2004;4:336-347.
2. Barber DL, Wherry EJ, Masopust D. et al. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature. 2006;439:682-687.
3. Day CL, Kaufmann DE, Kiepiela P, et al. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature. 2006;443:350-354.
4. + T cells leads to reversible immune dysfunction. Nat Med. 2006;12:1198-1202.
5. + T cell survival in HIV infection. J Exp Med. 2006;203: 2281-2292.
6. Freeman GJ, Wherry EJ, Ahmed R, Sharpe AH. Reinvigorating exhausted HIV-specific T cells via PD-1-PD-1 ligand blockade. J Exp Med. 2006; 203:2223-2227.
7. Dong H, Strome SE, Salomao DR. et al. Tumorassociated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med. 2002;8:793-800.
8. Hirano F, Kaneko K, Tamura H, et al. Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. Cancer Res. 2005;65:1089-1096.
9. Ohigashi Y, Sho M. Yamada Y, et al. Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer. Clin Cancer. Res. 2005; 11:2947-2953.
10. Thompson RH, Dong H, Lohse CM, et al. PD-1 is expressed by tumor-infiltrating immune cells and is associated with poor outcome for patients with renal cell carcinoma. Clin Cancer Res. 2007;13: 1757-1761.
11. Poppema S, van den Berg A. Interaction between host T cells and Reed-Sternberg cells in Hodgkin lymphomas. Semin Cancer Biol. 2000;10:345-350.
12. Nishikori M, Maesako Y, Ueda C, Kurata M, Uchiyama T, Ohno H. High-level expression of BCL3 differentiates t(2;5)(p23;q35)-positive anaplastic large cell lymphoma from Hodgkin disease. Blood. 2003;101:2789-2796.
13. Maesako Y, Uchiyama T. Ohno H. Comparison of gene expression profiles of lymphoma cell lines from transformed follicular lymphoma. Burkitt's lymphoma and de novo diffuse large B-cell lymphoma. Cancer Sci. 2003;94:774-781.
14. Konishi J. Yamazaki K, Azuma M, Kinoshita I, Dosaka-Akita H, Nishimura M. B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression. Clin Cancer Res. 2004;10: 5094-5100.
15. Nishikori M, Ohno H, Haga H, Uchiyama T. Stimulation of CD30 in anaplastic large cell lymphoma leads to production of nuclear factor-κB p52, which is associated with hyperphosphorylated Bcl-3. Cancer Sci. 2005;96:487-497.
16. Dorfman DM, Brown JA, Shahsafaei A, Freeman GJ. Programmed death-1 (PD-1) is a marker of germinal center-associated T cells and angioimmunoblastic T-cell lymphoma. Am J Surg Pathol. 2006;30:802-810.
17. Marshall NA, Christie LE, Munro LR, et al. Immunosuppressive regulatory T cells are abundant in the reactive lymphocytes of Hodgkin lymphoma. Blood. 2004;103:1755-1762.
18. Alvaro T Lejeune M. Salvado MT, et al. Outcome in Hodgkin's lymphoma can be predicted from the presence of accompanying cytotoxic and regulatory T cells. Clin Cancer Res. 2005;11:1467-1473.
19. + T-cell function in Hodgkin lymphoma patients. Blood. 2006;108: 2280-2289.
20. Marshall NA, Culligan DJ, Tighe J, Johnston PW, Barker RN, Vickers MA. The relationships between Epstein-Barr virus latent membrane protein 1 and regulatory T cells in Hodgkin's lymphoma. Exp Hematol. 2007;35:596-604.
21. Juszczynski P, Ouyang J, Monti S, et al. The API-dependent secretion of galectin-1 by Reed Sternberg cells fosters immune privilege in classical Hodgkin lymphoma. Proc Natl Acad Sci U SA. 2007;104:13134-13139.
22. + T cells in B-cell non-Hodgkin lymphoma. Blood. 2006;107:3639-3646.
23. Okazaki T, Maeda A. Nishimura H. Kurosaki T Honjo T, PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine. Proc Natl Acad Sci U S A. 2001;98:13866-13871.
24. +T cells in Hodgkin lymphoma. Blood. 2007;110:3226-3233.
25. Bollard CM, Aguilar L, Straathof KC, et al. Cytotoxic T lymphocyte therapy for Epstein-Barr virus+ Hodgkin's disease. J Exp Med. 2004:200: 1623-1633.